News

Knee Surgeries: High Costs, Low Benefits Persist

Knee Surgeries: High Costs, Low Benefits Persist

Stubborn Knee Surgeries Challenge the System

Hey, if you ask me, some folks in healthcare are still stuck in the Stone Age when it comes to dealing with knee issues. We're talking about a stubborn persistence of unnecessary meniscus surgeries, costing the U.S. around $4 billion—yep, with a 'b'—while offering little benefit over simpler treatments. A new report dives into this headfirst, showing geographic discrepancies like something out of a reality TV show: where you live could determine whether you get an unnecessary procedure or not. And here we are thinking evidence-based medicine was the creed the docs swore to follow!

"Improvement is possible, even when one in five patients still undergoes needless surgery." — Julie Scherer, PhD, Chief Data Scientist at Motive

The Variation Puzzle in Surgical Practices

Motive Medical Intelligence pulled no punches with a new analysis of 100 million insurance claims, highlighting how arbitrary state borders translate into disparities in medical practice. South Dakota leads the pack with nearly half of eligible patients receiving unnecessary surgery, while places like New Jersey have whittled it down to about 19%. Here’s a thought—if some places can get it right, what's holding the rest back?

  • Top performers: New Jersey (19%), California (20%), Florida (22%).
  • Worst offenders: South Dakota (46%), Iowa (42%), Wisconsin (42%).

Surprised? Don't be. It's an old tale of evidence based medicine meeting the molasses-in-January pace of actual change. The clinical evidence is as clear as day: for many middle-aged adults with age-related meniscal tears, surgery does zilch compared to physical therapy.

Doctors at a Crossroads: To Cut or Not to Cut?

Here's the crux of the chaos: these procedures keep happening despite longstanding guidelines from the American Academy of Orthopaedic Surgeons advising restraint. But what's missing? A medical cavalcade embracing groundbreaking results from the likes of the METEOR and FIDELITY trials. These studies laid down the gauntlet, showing that surgery was no better than physical therapy or, brace yourselves, fake surgery.

The sham surgery, a placebo if you will, proved to be as effective as the real thing. That should get some eyebrows raising, right?

Navigating Toward Evidence-Based Improvements

Have U.S. doctors become overly tech-happy, mistaking MRIs as crystal balls? Well, a lot needs to be said about tugging them back to planet reality. The spread of resources like Motive’s Practicing Wisely aims to shed that light where it’s dimmest, mapping out clinician performance against solid gold standards.

This is all to help cut down a jaw-dropping $400 billion in medical wastage a year in good ol’ America. Yup, it turns out we've got a lot of loose pocket change rolling around doing nothing for no one. But it’s not just about figures. Think of the human side—fewer surgeries mean less risk for patients and less wasted recovery time.

"Doctors have a duty to incorporate such convincing evidence into their practice." — Rich Klasco, MD, Chief Medical Officer at Motive

Healthcare Must Evolve to Cut Unnecessary Costs

Beneath all this data and geographical inconsistencies lies a healthcare system begging for change, echoing the cries of warrior ethos to embrace smarter, evidence-driven medicine. It goes beyond pulling back the curtain on low-value procedures—it's about pushing forward, leveling the field so every patient, regardless of zip code, receives the quality of care they deserve.

In an era where the term ‘value-based care’ doesn’t just carry weight, but the hopes of a more efficient system, there seems to be ample room for improvement. The path is there, cut it right or risk getting left behind in the surgical dust bin.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BioVid Debuts AI to Mimic Physician Decision-Making

Updated Category News Views 47

Revolutionizing Understanding: BioVid Mimetics™ Now here's something that's shaking the research tree: BioVid's launching Mimetics™, and it's a big deal. They've come up with AI that can mirror how physicians think and decide. This ain't your run-of-the-mill tech stuff—it's groundbreaking in understanding physician decision-making. The Core: How Do Doctors Really...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 111

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
AZ Health Workers Step Up for Community Wellness

Updated Category News Views 4

Health Screenings: A Step Before the Hospital Sometimes it's the basics, like a plain old health screening, that can shift the tides from crisis to care. That's exactly where AZ Blue Health Choice and Zeihan ProHealth come into the picture, aiming to pin those health concerns before they spiral out of control. For your average Arizonan who finds healthcare as elusive as a...

Continue Reading
Enigmata Innovates AI Security with Finovifi Tie-Up

Updated Category News Views 94

Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...

Continue Reading
Podcast Giants Converge in Tennessee for POD U Summit

Updated Category News Views 57

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Continue Reading
Home Insurance Gaps: Risky Assumptions Uncovered

Updated Category News Views 53

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Continue Reading
Americas Cardroom Smashes Prize Pools; Bahamas Up Next

Updated Category News Views 49

Ah, poker. Where dreams are won with a flick of the wrist and a well-placed bluff. This week, it was all eyes on Americas Cardroom’s Dual Venom PKOs, and let me tell you, they didn't just meet expectations—they chewed them up and spat them out like yesterday's jam. Two Titans Crowned in Poker Showdown The action wrapped up with a jaw-dropping $6,862,500 prize pool....

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 37

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
Savvy Moves: Avoiding Pitfalls When Buying Used Vans

Updated Category News Views 14

When you're eyeing a used work van, don't just kick the tires and jot down the mileage—there's a whole backyard BBQ checklist you need to chew through. Tony Collichio, the work van guru from Spencerport, lays it down for us, highlighting key questions to ask before pulling out the checkbook. And let me tell you, these aren’t your everyday 'how does it drive?' queries....

Continue Reading
Abbott's Oncodetect Test: Game-Changer for Cancer Recurrence

Updated Category News Views 4

Pioneering Progress in Colorectal Cancer Detection There's a new player in the world of cancer diagnostics, and it's setting a fresh standard. Abbott's Oncodetect test, featured at the ESMO Congress, has shown a profound leap in sensitivity—30 percent over the older whole-exome sequencing approach. For those doing the math on the stock charts, Abbott (NYSE: ABT) is...

Continue Reading

Top 5 Most Recently Viewed Articles

Clare Locke Advocates for Megan Thee Stallion in Defamation Case

Updated Category News Views 111

Clare Locke LLP Champions Megan Thee Stallion's Defamation Case Clare Locke LLP, a respected name in defamation law, has taken a bold step to support Megan Thee Stallion's pursuit of justice against Milagro Cooper. The firm has filed a motion for leave to present an amicus brief that specifically endorses Megan's effort to have a jury's defamation ruling reinstated. This...

Continue Reading
Bankers Signal Looming Economic Challenges Amid Uncertainty

Updated Category News Views 167

Bankers Signal Looming Economic Challenges Amid Uncertainty Interest rate fluctuations, credit quality, and tariffs are significant concerns for financial institutions. A recent survey highlights the anxiety among bankers regarding the economic climate and impending recession. Survey Highlights Economic Fears According to a survey from fintech IntraFi, which gathered...

Continue Reading
Dave Portnoy Questions Elon Musk Amid Tesla's Plummeting Stock

Updated Category News Views 162

Tesla's Stock Dilemma: Portnoy's Concerns Tesla’s stock, designated as TSLA, has recently experienced a significant decline, stirring up discussions among investors and enthusiasts alike. Dave Portnoy, the founder of Barstool Sports, has voiced his frustration regarding this situation, bringing forth some pointed questions about Elon Musk’s priorities. In a recent...

Continue Reading
Akropolis Group's Credit Rating Affirmed Amid Strategic Changes

Updated Category News Views 88

Akropolis Group’s Robust Credit Rating Amid Strategic Reassessments Renowned international credit rating agency S&P Global Ratings recently evaluated the financial outlook for Akropolis Group, a prominent player in the real estate development and management sector. This assessment took into account significant structural governance changes within the Vilniaus Prekyba...

Continue Reading
Arcutis Takes a Significant Step with ZORYVE Cream for Kids

Updated Category News Views 156

Arcutis Advances ZORYVE® Cream for Pediatric Use Arcutis Biotherapeutics, Inc. is making headlines with its recent submission of a supplemental New Drug Application (sNDA) aimed at expanding the use of ZORYVE (roflumilast) cream 0.3% to treat plaque psoriasis in children as young as 2 years old. If approved, ZORYVE would be the first topical PDE4 inhibitor specifically...

Continue Reading